Solutions

Patent_Extension_BG.png

Patent Extension

Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to “extend” their patents through Technology Transfer. Our additive manufacturing approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.

Our “Patent Extension” through Technology Transfer solution is for registered pharmaceutical drugs on the market.

Laxxon's technology optimizes the product and generates a new registration

Launch of new product generation as the ancestral product is coming off patent

Rebranding efforts transfer sales to new improved product generation

New and improved patented product prevents any loss of sales

Generates new and potentially higher revenue from optimized product

Strategic Commercialization

Laxxon offers three disruptive avenues for strategic opportunities within the pharmaceutical industry:

New_Drug_Innovation_BG.png

New Drug Innovation

Laxxon serves as a research, development, engineering, and manufacturing partner for pharmaceutical companies seeking new drug development. SPID®- Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production without a change in the manufacturing process.

Laxxon offers state-of-the-art manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development. Laxxon's technology can provide the ability to create new drug delivery systems using APIs previously incompatible with conventional manufacturing processes.

SPID®-Technology

SPID® (Screen Printed Innovative Drug) Technology is Laxxon’s additive 3D screen-printing and manufacturing process. With our patented technology, we can produce a generation of smart drug delivery systems (DDSs) with tailored pharmacokinetics based on advanced geometric internal structures, heterogeneous distribution of active ingredients, and choice of materials.

Laxxon has both an external pipeline as well as an in-house Advanced Patented Generic pipeline. All products created with our SPID®-Technology manufacturing approach ­– whether engineered in-house or with an external partner – are patent protected.

Patent_Extension_BG.png

Patent Extension

Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to “extend” their patents through Technology Transfer. Our additive manufacturing approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.

Our “Patent Extension” through Technology Transfer solution is for registered pharmaceutical drugs on the market.

Laxxon's technology optimizes the product and generates a new registration

Launch of new product generation as the ancestral product is coming off patent

Rebranding efforts transfer sales to new improved product generation

New and improved patented product prevents any loss of sales

Generates new and potentially higher revenue from optimized product

New_Drug_Innovation_BG.png

New Drug Development

Laxxon serves as a research, development, engineering, and manufacturing partner for pharmaceutical companies seeking new drug development. SPID®- Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production without a change in the manufacturing process.

Laxxon offers state-of-the-art manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development. Laxxon's technology can provide the ability to create new drug delivery systems using APIs previously incompatible with conventional manufacturing processes.

Advanced Patented Generics

Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects.

Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.

The ideal 505(b)(2) candidates are:

Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration

Drugs with new active ingredients (in some cases)

Drugs with new indications

New combination product

Prodrugs of an existing drug

Advanced Patented Generics

Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects.

Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.

The ideal 505(b)(2) candidates are:

Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration

Drugs with new active ingredients (in some cases)

Drugs with new indications

New combination product

Prodrugs of an existing drug

Laxxon Medical is disrupting the current pharmaceutical drug delivery and manufacturing landscape through our innovative, patented SPID®-Technology (Screen Printing Innovational Drug Technology).

Stay
Informed

Subscribe for updates on our latest developments.

Thanks for submitting!

Contact Us

We're always eager to chat with potential investors and industry partners. Contact us for any additional information you need.

Thanks for submitting!

All Rights Reserved © 2022 by Laxxon Medical

  • Twitter
  • LinkedIn

135 E 57th Street,

New York, New York 10022

Contact Us

We're always eager to chat with potential investors and industry partners. Contact us for any additional information you need.